{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:29:46Z","timestamp":1794018586214,"version":"4.8.0"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.critrevonc.2026.105347","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T16:08:58Z","timestamp":1777306138000},"page":"105347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Emerging treatment paradigms for gastric cancer peritoneal metastasis in the era of multimodal precision therapy"],"prefix":"10.1016","volume":"223","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2558-6871","authenticated-orcid":false,"given":"Qiuli","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangjun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5022-9215","authenticated-orcid":false,"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.critrevonc.2026.105347_bib1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","article-title":"Gastric Cancer, Version 2.2025, NCCN clinical practice guidelines in oncology","volume":"23","author":"Ajani","year":"2025","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.critrevonc.2026.105347_bib2","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","article-title":"Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications","volume":"20","author":"Alyami","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib3","series-title":"AJCC Cancer Staging Manual","year":"2017"},{"key":"10.1016\/j.critrevonc.2026.105347_bib4","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105347_bib5","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/bjs\/znab200","article-title":"Prognosis of poorly cohesive gastric cancer after complete cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (CYTO-CHIP study)","volume":"108","author":"Bonnot","year":"2021","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.critrevonc.2026.105347_bib6","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105347_bib7","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s12943-024-02196-4","article-title":"Transcriptional landscape and predictive potential of long noncoding RNAs in peritoneal recurrence of gastric cancer","volume":"23","author":"Cai","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105347_bib8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1515\/pp-2022-0111","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer: a randomized multicenter phase III trial PIPAC VEROne","volume":"7","author":"Casella","year":"2022","journal-title":"Pleura Perito"},{"key":"10.1016\/j.critrevonc.2026.105347_bib9","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","article-title":"Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials","volume":"7","author":"Chao","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib10","article-title":"Pressurized intraperitoneal aerosol chemotherapy in advanced gastric cancer with peritoneal metastases: a comprehensive meta-analysis of feasibility, efficacy, and safety","volume":"13","author":"Chen","year":"2025","journal-title":"Gastroenterol. Rep. (Oxf. )"},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105347_bib11","article-title":"Accurate and rapid detection of peritoneal metastasis from gastric cancer by AI-assisted stimulated Raman molecular cytology","volume":"10","author":"Chen","year":"2023","journal-title":"Adv. Sci. (Weinh. )"},{"key":"10.1016\/j.critrevonc.2026.105347_bib12","series-title":"Guidelines of Chinese Society of Clinical Oncology (CSCO): Gastric Cancer 2025","author":"Chinese Society of Clinical Oncology Guidelines Working Committee","year":"2025"},{"key":"10.1016\/j.critrevonc.2026.105347_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2017.03.030","article-title":"The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer","volume":"79","author":"Desiderio","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105347_bib14","article-title":"Transcriptomics-based liquid biopsy for early detection of recurrence in locally advanced gastric cancer","volume":"11","author":"Ding","year":"2024","journal-title":"Adv. Sci. (Weinh. )"},{"key":"10.1016\/j.critrevonc.2026.105347_bib15","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/annonc\/mdz001","article-title":"Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer","volume":"30","author":"Dong","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib16","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S1470-2045(25)00287-6","article-title":"Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study","volume":"26","author":"Elimova","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib17","doi-asserted-by":"crossref","DOI":"10.1515\/pp-2018-0116","article-title":"PIPAC EstoK 01: pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin (PIPAC C\/D) in gastric peritoneal metastasis: a randomized and multicenter phase II study","volume":"3","author":"Eveno","year":"2018","journal-title":"Pleura Perito"},{"key":"10.1016\/j.critrevonc.2026.105347_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn2231","article-title":"Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice","volume":"14","author":"Evgin","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105347_bib19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40364-024-00640-7","article-title":"Oncological characteristics, treatments and prognostic outcomes in MMR-deficient colorectal cancer","volume":"12","author":"Fan","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.critrevonc.2026.105347_bib20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13045-024-01628-4","article-title":"Personalized nanovaccines for treating solid cancer metastases","volume":"17","author":"Feng","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004001","article-title":"Ascites and resistance to immune checkpoint inhibition in dMMR\/MSI-H metastatic colorectal and gastric cancers","volume":"10","author":"Fuc\u00e0","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105347_bib22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105347_bib23","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib24","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10120-021-01227-z","article-title":"Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial","volume":"25","author":"Fuchs","year":"2022","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.critrevonc.2026.105347_bib25","first-page":"717","article-title":"[Chinese expert consensus on the diagnosis and treatment of peritoneal metastasis of gastric cancer (2023 edition)]","volume":"26","author":"Gastric Cancer Committee of China Anti Cancer Association","year":"2023","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi"},{"key":"10.1016\/j.critrevonc.2026.105347_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2021.5340","article-title":"18F-fludeoxyglucose-positron emission tomography\/computed tomography and laparoscopy for staging of locally advanced gastric cancer: a multicenter prospective Dutch cohort study (PLASTIC)","volume":"156","author":"Gertsen","year":"2021","journal-title":"JAMA Surg."},{"key":"10.1016\/j.critrevonc.2026.105347_bib27","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1245\/s10434-022-13010-0","article-title":"Treatment of peritoneal metastasis with pressurized intraperitoneal aerosol chemotherapy: results from the prospective PIPAC-OPC2 study","volume":"30","author":"Graversen","year":"2023","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105347_bib28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","article-title":"Gastric cancer treatment: recent progress and future perspectives","volume":"16","author":"Guan","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib29","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1200\/JCO.2015.62.6598","article-title":"Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013\/LOGiC--a randomized phase III trial","volume":"34","author":"Hecht","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib30","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","article-title":"Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial","volume":"36","author":"Ishigami","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105347_bib32","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105347_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2026.02.003","article-title":"Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649","author":"Janjigian","year":"2026","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib34","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10120-011-0041-5","article-title":"Japanese classification of gastric carcinoma: 3rd English edition","volume":"14","author":"Japanese Gastric Cancer Association","year":"2011","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.critrevonc.2026.105347_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","article-title":"Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition)","volume":"26","author":"Japanese Gastric Cancer Association","year":"2023","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.critrevonc.2026.105347_bib36","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.ejso.2020.11.139","article-title":"Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: a single-center retrospective analysis of 125 patients","volume":"47","author":"Ji","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib37","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.32269","article-title":"Noninvasive prediction of occult peritoneal metastasis in gastric cancer using deep learning","volume":"4","author":"Jiang","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.critrevonc.2026.105347_bib38","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2589-7500(22)00040-1","article-title":"Predicting peritoneal recurrence and disease-free survival from CT images in gastric cancer with multitask deep learning: a retrospective study","volume":"4","author":"Jiang","year":"2022","journal-title":"Lancet Digit. Health"},{"key":"10.1016\/j.critrevonc.2026.105347_bib39","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105347_bib40","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib41","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO-24-02463","article-title":"Phase II study (NO LIMIT, WJOG13320G) of first-line nivolumab plus low-dose ipilimumab for microsatellite instability-high advanced gastric or esophagogastric junction cancer","volume":"43","author":"Kawakami","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib42","article-title":"Retlirafusp alfa: first approval","author":"Keam","year":"2026","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105347_bib43","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s12885-021-08058-2","article-title":"Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data","volume":"21","author":"Kim","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105347_bib44","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/SLA.0000000000002040","article-title":"Lauren histologic type is the most important factor associated with pattern of recurrence following resection of gastric adenocarcinoma","volume":"267","author":"Lee","year":"2018","journal-title":"Ann. Surg."},{"key":"10.1016\/j.critrevonc.2026.105347_bib45","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction","volume":"34","author":"Li","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105347_bib46","first-page":"650","article-title":"China Anti-Cancer Association guidelines for holistic integrative management of gastric cancer (2024 abridged version)","volume":"51","author":"Liang","year":"2024","journal-title":"Chin. J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105347_bib47","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1038\/s41591-025-03783-8","article-title":"CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial","volume":"31","author":"Liu","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105347_bib48","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12943-017-0742-4","article-title":"Factors involved in cancer metastasis: a better understanding to \u201cseed and soil\u201d hypothesis","volume":"16","author":"Liu","year":"2017","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105347_bib49","article-title":"Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): prespecified interim analysis of a randomized, phase III clinical trial","author":"Liu","year":"2026","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib50","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib51","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12943-023-01715-z","article-title":"Clinical application and detection techniques of liquid biopsy in gastric cancer","volume":"22","author":"Ma","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105347_bib52","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006654","article-title":"Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors","volume":"11","author":"Ma","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105347_bib53","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.3390\/jcm11082247","article-title":"Real-world data of trastuzumab deruxtecan for advanced gastric cancer: a multi-institutional retrospective study","volume":"11","author":"Matsumoto","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.critrevonc.2026.105347_bib54","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.2147\/CMAR.S193739","article-title":"Is ramucirumab and paclitaxel therapy beneficial for second-line treatment of metastatic gastric or junctional adenocarcinoma for patients with ascites? Analysis of RAINBOW phase 3 trial data","volume":"11","author":"Muro","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.critrevonc.2026.105347_bib55","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s10120-025-01640-8","article-title":"Neoantigen mRNA vaccines induce progenitor-exhausted T cells that support anti-PD-1 therapy in gastric cancer with peritoneal metastasis","volume":"28","author":"Nagaoka","year":"2025","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.critrevonc.2026.105347_bib56","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s10555-025-10265-3","article-title":"Molecular mechanisms of metastatic peritoneal dissemination in gastric adenocarcinoma","volume":"44","author":"Ng","year":"2025","journal-title":"Cancer Metastas-.-. Rev."},{"key":"10.1016\/j.critrevonc.2026.105347_bib57","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1572-0241.1999.873_b.x","article-title":"Regional lymph node metastasis as a predictor of peritoneal carcinomatosis in patients with Borrmann type IV gastric carcinoma","volume":"94","author":"Otsuji","year":"1999","journal-title":"Am. J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105347_bib58","doi-asserted-by":"crossref","first-page":"S1250","DOI":"10.1016\/j.annonc.2024.08.2302","article-title":"LBA60 Phase III study of SHR-1701 versus placebo in combination with chemotherapy as first-line therapy for HER2-negative gastric\/gastroesophageal junction adenocarcinoma","volume":"35","author":"Peng","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib59","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1021\/acsnano.0c09938","article-title":"Immune reprogramming precision photodynamic therapy of peritoneal metastasis by scalable stem-cell-derived extracellular vesicles","volume":"15","author":"Pinto","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.critrevonc.2026.105347_bib60","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105347_bib61","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","article-title":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","volume":"405","author":"Qi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105347_bib62","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2026.105347_bib63","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1200\/JCO.22.02867","article-title":"Effect of hyperthermic intraperitoneal chemotherapy on cytoreductive surgery in gastric cancer with synchronous peritoneal metastases: the phase III GASTRIPEC-I trial","volume":"42","author":"Rau","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib64","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib65","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.7150\/thno.88335","article-title":"Evaluation of FAPI PET imaging in gastric cancer: a systematic review and meta-analysis","volume":"13","author":"Ruan","year":"2023","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105347_bib66","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1470-2045(24)00636-3","article-title":"Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial","volume":"26","author":"Ruan","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib67","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2013.53.6136","article-title":"Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in asian populations: TyTAN--a randomized, phase III study","volume":"32","author":"Satoh","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib68","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105347_bib69","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/s41591-024-03450-4","article-title":"First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial","volume":"31","author":"Shen","year":"2025","journal-title":"Nat. Med."},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105347_bib70","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105347_bib71","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib72","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105347_bib73","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1007\/s10120-024-01518-1","article-title":"Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma","volume":"27","author":"Shitara","year":"2024","journal-title":"Gastric Cancer"},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105347_bib74","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1200\/JCO-25-00748","article-title":"Lenvatinib plus pembrolizumab and chemotherapy versus chemotherapy in advanced metastatic gastroesophageal adenocarcinoma: the phase III, randomized LEAP-015 study","volume":"43","author":"Shitara","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib75","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1056\/NEJMoa2503119","article-title":"Trastuzumab deruxtecan or ramucirumab plus paclitaxel in gastric cancer","volume":"393","author":"Shitara","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"2_","key":"10.1016\/j.critrevonc.2026.105347_bib76","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1200\/JCO.2026.44.2_suppl.378","article-title":"Modeling analysis of RATIONALE-305: impact of peritoneal metastasis representation on clinical outcomes in patients treated with tislelizumab plus chemotherapy with gastric cancer\/gastroesophageal junction cancer","volume":"44","author":"Sonbol","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib77","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ctrv.2016.06.007","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of gastrointestinal cancers with peritoneal metastases: progress toward a new standard of care","volume":"48","author":"Sugarbaker","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105347_bib78","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/ijc.28373","article-title":"Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors","volume":"134","author":"Thomassen","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105347_bib79","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1245\/s10434-025-17518-z","article-title":"National guidelines for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal malignancies: a worldwide systematic review and recommendations of strength analysis","volume":"32","author":"Tonello","year":"2025","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2024.108346","article-title":"Standardizing eligibility and patient selection for Pressurized Intraperitoneal Aerosol Chemotherapy: A Delphi consensus statement","volume":"50","author":"Tozzi","year":"2024","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib81","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"Van Cutsem","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib82","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cac2.12516","article-title":"The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun. (Lond)"},{"key":"10.1016\/j.critrevonc.2026.105347_bib83","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib84","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1007\/s12325-025-03142-6","article-title":"Pembrolizumab in patients of Chinese descent with microsatellite instability-high\/mismatch repair-deficient advanced solid tumors: KEYNOTE-158 final analysis","volume":"42","author":"Wu","year":"2025","journal-title":"Adv. Ther."},{"key":"10.1016\/j.critrevonc.2026.105347_bib85","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2026.105347_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2022.10.004","article-title":"KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer","volume":"178","author":"Xu","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105347_bib87","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41389-023-00466-2","article-title":"Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy","volume":"12","author":"Xu","year":"2023","journal-title":"Oncogenesis"},{"key":"10.1016\/j.critrevonc.2026.105347_bib88","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S2468-1253(21)00313-7","article-title":"Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial","volume":"6","author":"Xu","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib89","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2967\/jnumed.123.266329","article-title":"Fibroblast activation protein-targeted PET\/CT with 18F-fibroblast activation protein inhibitor-74 for evaluation of gastrointestinal cancer: comparison with 18F-FDG PET\/CT","volume":"65","author":"Xu","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"4_","key":"10.1016\/j.critrevonc.2026.105347_bib90","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1200\/JCO.2025.43.4_suppl.327","article-title":"Intraperitoneal and intravenous paclitaxel plus S-1 versus intravenous paclitaxel plus S-1 in gastric cancer patients with peritoneal metastasis: results from the multicenter, randomized, phase 3 DRAGON-01 trial","volume":"43","author":"Yan","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib91","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006280","article-title":"Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases","volume":"11","author":"Yang","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105347_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.omto.2023.100734","article-title":"Peritoneal-directed chimeric oncolytic virus CF17 prevents malignant ascites and improves survival in gastric cancer peritoneal metastases","volume":"31","author":"Yang","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.critrevonc.2026.105347_bib93","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ejso.2006.03.007","article-title":"Neoadjuvant treatment of gastric cancer with peritoneal dissemination","volume":"32","author":"Yonemura","year":"2006","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib94","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1245\/s10434-016-5487-6","article-title":"Effects of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy and neoadjuvant intraperitoneal\/systemic chemotherapy on peritoneal metastases from gastric cancer","volume":"24","author":"Yonemura","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105347_bib95","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1186\/s12885-020-07601-x","article-title":"Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study","volume":"20","author":"Yu","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105347_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103731","article-title":"Intraperitoneal and intravenous paclitaxel plus S-1 and sintilimab as first-line treatment for gastric cancer with peritoneal metastasis: a single-arm phase 2 trial (DRAGON-09)","volume":"91","author":"Yuan","year":"2026","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.critrevonc.2026.105347_bib97","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1001\/jama.2024.28463","article-title":"First-line sugemalimab plus chemotherapy for advanced gastric cancer: the GEMSTONE-303 randomized clinical trial","volume":"333","author":"Zhang","year":"2025","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105347_bib98","article-title":"Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy","volume":"21","author":"Zhang","year":"2025","journal-title":"Hum. Vaccin. Immunother."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105347_bib99","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s10120-025-01631-9","article-title":"Asian consensus on normothermic intraperitoneal and systemic treatment for gastric cancer with peritoneal metastasis","volume":"28","author":"Zhu","year":"2025","journal-title":"Gastric Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:00:35Z","timestamp":1780038035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826002349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":99,"alternative-id":["S1040842826002349"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105347","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging treatment paradigms for gastric cancer peritoneal metastasis in the era of multimodal precision therapy","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105347","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105347"}}